Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor
Michael J. Cavnar, Kenneth Seier, Mithat Gönen, Christina Curtin, Vinod P. Balachandran, William D. Tap, Cristina R. Antonescu, S. J. Singer, Ronald P. DeMatteo
Topics & Concepts
MedicineGiSTHazard ratioImatinibInternal medicineOncologyClinical endpointStromal tumorUnivariate analysisAdjuvant therapyProportional hazards modelPrimary tumorImatinib mesylateGastroenterologyMultivariate analysisStromal cellCancerConfidence intervalMetastasisClinical trialMyeloid leukemiaGastrointestinal Tumor Research and TreatmentGastrointestinal disorders and treatmentsGastrointestinal Bleeding Diagnosis and Treatment